Senate LDA lobbying filing
ELI LILLY AND COMPANY
Reported income
not reported
Reported expenses
$1.90M
Tracked program mentions1
Quoted activity text is clipped to a short extract; each filing’s full description is under Lobbying activities below.
- Making, Maintaining, Supply Chain and Logistics0602025Ematched: “Supply|Chain”matched 2+ title words
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and…
Lobbying activities7
Copyright/Patent/TrademarkCPT
Pharmaceutical intellectual property issues
Consumer Issues/Safety/ProductsCSP
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Health IssuesHCR
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Medicare/MedicaidMMM
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
PharmacyPHA
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Taxation/Internal Revenue CodeTAX
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping
Trade (domestic/foreign)TRD
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Lobbyists10
- ASKIA SURUMArevolving door
Chief of Staff, Rep. Marc Veasey (2017-2021); Deputy Staff Director, Ways and Means Committee (2007-2014); Deputy Staff Director, House Rules Committee (2001-2007); Legislative Director, Rep. Martin Frost (2000-2001)
- DAVID TALBOT
- FRANK DE LIMA
- HEATHER CLARK
- JUAN MACHADOrevolving door
Senate Finance Committee; Professional Staff and Senior Health Advisor, Department of Health & Human Services, Health Insurance Specialist
- PAUL BURKHEAD
- SARAH KYLErevolving door
Legislative Asst, Senator Bayh (2007-2011); Legislative Asst, Rep Tim Roemer (2000-2003)
- SHANNON STEHOUWERrevolving door
Staff, Senator John Hoeven (2014-2016); Staff, Rep. Mike Rogers (2010-2014)
- SHAWN O'NEAIL
- THOMAS ROBERGErevolving door
Legislative Counsel (2002-2004 - Senator Peter Fitzgerald)
Source: U.S. Senate Lobbying Disclosure Act database. Dollar figures (underlined) cite the filing record on lda.senate.gov — click to view the citation. Amounts shown as “not reported” are absent from the filing itself.